Testimony and Public Comments
PhRMA Testimony and Public Comments
Read public addresses and testimony from PhRMA regarding key issues in the biopharmaceutical industry. Click on the links below to read.
The Pharmaceutical Research and Manufacturers (PhRMA) commends the House Judiciary Committee for considering legislation to curb abusive patient litigation. We appreicate the opportunity to work with you toward this goal. Read more.
The Pharmaceutical Research and Manufacturers (PhRMA) and its members are committed to enhancing responsible sharing of clinical trial data produced by biopharmaceutical companies and other research sponsors, and we appreciate the opportunity to provide testimony to the Committee on Stragies for Responsible Sharing of Clinical Trial Data (the Committee). Read more.
The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit these comments in response to the issuance by the Food and Drug Administration (FDA) of a request for comments in its Federal Register Notice entitled “Draft Guidance for Industry on Expedited Programs for Serious Conditions—Drugs and Biologics; Availability” (hereinafter, “Draft Guidance on Expedited Programs”) Read more.
The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit these comments in response to the Food and Drug Administration’s (FDA) request for comments on priorities for the development and implementation of solutions to the challenges of antibacterial drug development. PhRMA is a voluntary, nonprofit association that represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Read more.
Chairman Nelson, Ranking Member Collins, and Members of the Committee, thank you for inviting me to testify on the Medicare prescription drug program, also known as Part D. Read more.